{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:48:29Z","timestamp":1776278909930,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.maturitas.2014.08.001","type":"journal-article","created":{"date-parts":[[2014,9,27]],"date-time":"2014-09-27T16:12:30Z","timestamp":1411834350000},"page":"343-348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Screening for osteoporosis after breast cancer: For whom, why and when"],"prefix":"10.1016","volume":"79","author":[{"given":"Florence A.","family":"Tr\u00e9mollieres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2014.08.001_bib0005","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2265.1992.tb01436.x","article-title":"Assessment of the risk of post-menopausal osteoporosis using clinical factors","volume":"36","author":"Ribot","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1677\/joe.1.06059","article-title":"Role of oestrogen in the regulation of bone turnover at the menarche","volume":"185","author":"Eastell","year":"2005","journal-title":"J Endocrinol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/oxfordjournals.epirev.a036116","article-title":"Endogenous hormones and breast cancer risk","volume":"15","author":"Berstein","year":"1993","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0020","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1001\/jama.1996.03540170048031","article-title":"Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures, Study of Osteoporotic Fractures","volume":"276","author":"Cauley","year":"1996","journal-title":"J Am Med Ass"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0025","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/jnci\/93.12.930","article-title":"Bone mass and breast cancer risk in older women: differences by stage at diagnosis","volume":"93","author":"Zmuda","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0378-5122(00)00133-X","article-title":"Association between breast cancer and bone mineral density: the Dubbo Osteoporosis Epidemiology Study","volume":"36","author":"Nguyen","year":"2000","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0035","first-page":"213","article-title":"Bone mineral density and endogenous hormones and risk of breast cancer in postmenopausal women (United States)","volume":"12","author":"Buist","year":"2001","journal-title":"Cancer Causes Cont"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2407-2-22","article-title":"Bone mineral density and the subsequent risk of cancer in the NHANES I follow-up cohort","volume":"2","author":"Nelson","year":"2002","journal-title":"BMC Cancer"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0045","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1023\/B:EJEP.0000036567.60387.39","article-title":"Bone mass density and risk of breast cancer and survival in older women","volume":"19","author":"Ganry","year":"2004","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0050","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/cncr.23674","article-title":"Hip bone density predicts breast cancer risk independently of Gail score","volume":"113","author":"Chen","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0055","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrazole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial","volume":"359","author":"ATAC Trialists\u2019 Group","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0060","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Th\u00fcrlimann","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0065","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bone mineral density, bone biomarkers and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study","volume":"8","author":"Coleman","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0070","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0075","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0080","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0021-9681(87)90061-0","article-title":"Risk of osteoporotic fractures in women with breast cancer: a population-based cohort study","volume":"40","author":"Utz","year":"1987","journal-title":"J Chron Dis"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0085","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bjc.6690188","article-title":"A high incidence of vertebral fracture in women with breast cancer","volume":"79","author":"Kanis","year":"1999","journal-title":"Br J Cancer."},{"key":"10.1016\/j.maturitas.2014.08.001_bib0090","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archinte.165.5.552","article-title":"Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study","volume":"165","author":"Chen","year":"2005","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.maturitas.2014.08.001_bib0095","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1200\/JCO.2007.15.7123","article-title":"Tamoxifen use and osteoporotic fracture risk: a population-based analysis","volume":"26","author":"Cooke","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.maturitas.2014.08.001_bib0100","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/02841860802167490","article-title":"Fracture risk in patients with different types of cancer","volume":"48","author":"Vestergaard","year":"2009","journal-title":"Acta Oncol."},{"key":"10.1016\/j.maturitas.2014.08.001_bib0105","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/jbmr.1556","article-title":"Fracture Risk in Women With Breast Cancer: A Population-Based Study","volume":"27","author":"Melton","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0110","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/annonc\/mdr356","article-title":"High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy","volume":"23","author":"Bouvard","year":"2012","journal-title":"Ann Oncol."},{"key":"10.1016\/j.maturitas.2014.08.001_bib0115","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/jgs.12269","article-title":"Fracture risk in older, long-term survivors of early-stage breast cancer","volume":"61","author":"Pawloski","year":"2013","journal-title":"J Am Geriatr Soc."},{"key":"10.1016\/j.maturitas.2014.08.001_bib0120","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0125","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJM199809103391104","article-title":"Endogenous hormones and the risk of hip and vertebral fractures among older women","volume":"339","author":"Cummings","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0130","first-page":"2239","article-title":"Associations between low levels of serum estradiol, bone density and fractures among elderly women: the Study of Osteoporotic fractures","volume":"83","author":"Ettinger","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0135","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1359\/jbmr.2002.17.1.172","article-title":"Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women","volume":"178","author":"Hesmati","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0140","first-page":"385","article-title":"Structural analysis of the gene encoding human aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis","volume":"19","author":"Means","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0145","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1093\/annonc\/mdi322","article-title":"Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial","volume":"16","author":"Banerjee","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0150","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","article-title":"Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years with adjuvant tamoxifen: a companion study to NCIC CTG MA.17","volume":"24","author":"Perez","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0155","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1200\/JCO.2005.07.097","article-title":"Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers and plasma lipids in patients with surgically resected early breast cancer","volume":"23","author":"Lonning","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0160","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.berh.2009.09.003","article-title":"Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer","volume":"23","author":"Ghazi","year":"2009","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0165","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/bjc.1990.58","article-title":"Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer","volume":"61","author":"Bruning","year":"1990","journal-title":"Br J Cancer"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0170","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","article-title":"Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients","volume":"15","author":"Saarto","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0175","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10549-005-3803-0","article-title":"Changes on bone mineral density after adjuvant treatment in women non-metastatic breast cancer","volume":"93","author":"Rodriguez-Rodriguez","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0180","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","article-title":"Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer","volume":"19","author":"Shapiro","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0185","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jnci\/djr242","article-title":"Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis","volume":"103","author":"Amir","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0190","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","article-title":"Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial","volume":"21","author":"Eastell","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0195","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0200","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100 month-analysis of the ATAC trial","volume":"9","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0205","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mdq541","article-title":"Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial","volume":"22","author":"Eastell","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0210","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years\u2019 adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet"},{"issue":"S7","key":"10.1016\/j.maturitas.2014.08.001_bib0215","doi-asserted-by":"crossref","first-page":"vii10","DOI":"10.1093\/annonc\/mdl941","article-title":"Switching to anastrozole versus continued tamoxifen treatment of early breast cancer, Updated results of the Italian tamoxifen anastrozole (ITA) trial","volume":"17","author":"Boccardo","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0220","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/annonc\/mdp033","article-title":"Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial","volume":"20","author":"Rabaglio","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0225","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/annonc\/mdu008","article-title":"Fracture incidence after 3 years of aromatase inhibitor therapy","volume":"25","author":"Bouvard","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0230","first-page":"131","article-title":"Risk factors for a first-incident radiographic vertebral fracture in women>or =65 years of age: the study of osteoporotic fractures","volume":"20","author":"Nevitt","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0235","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1200\/JCO.2004.08.148","article-title":"Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy","volume":"18","author":"Sverrisd\u00f3ttir","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0240","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.2005.02.3515","article-title":"Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status","volume":"24","author":"Vehmanen","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0245","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/j.ejca.2006.07.005","article-title":"Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study","volume":"42","author":"Geisler","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0250","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0255","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","article-title":"American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0260","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0265","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/annonc\/mdr017","article-title":"Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment","volume":"22","author":"Hadji","year":"2011","journal-title":"Ann Oncol"},{"issue":"S1","key":"10.1016\/j.maturitas.2014.08.001_bib0270","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","article-title":"Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group","volume":"34","author":"Reid","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0275","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1007\/s00198-011-1870-0","article-title":"Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper","volume":"23","author":"Rizzoli","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0280","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","author":"Coleman","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0285","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejca.2011.10.021","article-title":"The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials","volume":"48","author":"Yan","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0290","first-page":"70302- X","article-title":"Adjuvant zoledronic acide in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial","author":"Coleman","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0295","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.08.001_bib0300","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-009-0352-y","article-title":"Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study","volume":"118","author":"Ellis","year":"2009","journal-title":"Breast Cancer Res Treat"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037851221400262X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037851221400262X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:02:07Z","timestamp":1759914127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037851221400262X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S037851221400262X"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2014.08.001","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening for osteoporosis after breast cancer: For whom, why and when","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2014.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}